Back to Search
CHRISTOPHER TANGEN, D.O.
D.O.
Sports Medicine (Family Medicine) Physician
NPI: 1336344746IndividualAccepts Medicare
Specialties, Licenses & Credentials
Sports Medicine (Family Medicine) PhysicianPrimary
Family Medicine — Sports Medicine
Code: 207QS0010X
35-009402(OH)
Family Medicine Physician
Family Medicine
Code: 207Q00000X
58.001840(OH)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
DES MOINES UNIVERSITY OF OSTEOPATHIC MEDICINE AND HEALTH SCIENCES
Class of 2005
Research & Publications (20)
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
PMID 19371909·J Urol·2009
3-trial
Is there a standard of care for pathologic stage T3 prostate cancer?
PMID 19433682·J Clin Oncol·2009
8-other
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.
PMID 19167731·J Urol·2009
4-observational
Clinical trials: 'clinical integration': laudable, but challenging.
PMID 19498403·Nat Rev Urol·2009
8-other
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
PMID 19380444·J Clin Oncol·2009
3-trial
Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.
PMID 19100570·J Urol·2009
4-observational
Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
PMID 19475640·Prostate·2009
8-other
Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
PMID 19598210·Cancer·2009
8-other
Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.
PMID 18618736·Prostate·2008
8-other
Predicting prostate cancer risk through incorporation of prostate cancer gene 3.
PMID 18707724·J Urol·2008
8-other
The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794.
PMID 18930488·J Urol·2008
2-rct
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
PMID 18349405·J Clin Oncol·2008
5-case
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
PMID 18550097·J Urol·2008
2-rct
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
PMID 18383517·Cancer·2008
4-observational
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
PMID 18404692·Cancer·2008
8-other
Does the level of prostate cancer risk affect cancer prevention with finasteride?
PMID 18455628·Urology·2008
8-other
The Prostate Cancer Prevention Trial and the future of chemoprevention.
PMID 18353157·BJU Int·2008
8-other
Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
PMID 18957671·J Natl Cancer Inst·2008
8-other
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.
PMID 19138953·Cancer Prev Res (Phila)·2008
2-rct
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1611 S GREEN RD STE 160
SOUTH EUCLID, OH 44121 - Phone
- (440) 585-7146
Quick Facts
- NPI
- 1336344746
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 21
- Publications
- 20
Are you this provider?
Claim Your Profile